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1ABSTRACT
The Dietary Supplement Health and Education Act of 1994 (DSHEA) dramatically changed
the way dietary supplements are regulated in the United States. DSHEA created a new category
of products deﬁned as “dietary supplements,” and altered the way in which these products are
regulated in an attempt to promote consumer access to dietary supplements. By weakening the
FDA’s regulatory control of dietary supplements, DSHEA made it impossible for the FDA to insure
the safety of dietary supplements sold in the United States. DSHEA allows most supplements to
enter the market without ﬁrst being tested for safety, and once on the market, DSHEA makes
it very diﬃcult for the FDA to remove potentially dangerous dietary supplements. The FDA’s
inability to insure the safety of dietary supplements under DSHEA is exempliﬁed by its failed
eﬀorts to place tighter restrictions on the sale of dietary supplements containing ephedra alkaloids
(ephedra or ephedrine). Despite mounting evidence that supplements containing ephedra alkaloids
may be responsible for serious injury and death, the well-funded and politically-connected ephedra
industry has successfully fought oﬀ all FDA eﬀorts aimed at imposing tighter regulations on ephedra
supplements. Changes to existing law, including pre-market testing, mandatory reporting of adverse
events, and accurate content labels are necessary if the FDA is to fulﬁll its goal of policing consumer
safety.
2I.
INTRODUCTION
In the past couple of decades Americans have become increasingly health-conscious. In addition to par-
ticipating in physical exercise and modifying their eating habits, people today routinely rely on dietary
supplements to help them achieve their ﬁtness goals.1Whether their goals include increased strength and
speed for athletic competition, muscle growth, mental wellness or weight loss, there currently exists a di-
etary supplement on the market that purports to aid users reach the desired end results. Too often, however,
dietary supplements contribute to, or cause, serious health problems or even death instead of delivering the
promised health beneﬁts.
Although partly attributable to the heightened health-conscious attitude of many Americans, the exponen-
tial increase in the use and sales of dietary supplements comes largely as a result of loosened regulatory
control over the dietary supplement industry.2The Dietary Supplement Health and Education Act of 1994
(DSHEA)3weakened the Food and Drug Administration’s (FDA) regulatory control over dietary supple-
ments and allowed dietary supplement manufacturers to ﬂood the market with supplements that have no
proven beneﬁt to users, and some that evidence has shown to be potentially dangerous.4Eﬀorts by the FDA
1Pete Hartogs, Report: Dietary Supplement Warning System Lacking (Apr. 12, 2001), available at
http://www.cnn.com/2001/HEALTH/diet.ﬁtness/04/12/dietary.supplements/index.html (stating that 60 percent of Americans
take some sort of dietary supplement).
2From 1994 to 2000, after the passage of DSHEA, sales of dietary supplements rose by nearly 80 percent, from $8.8 billion
to $15.7 billion. Sally Squires, Making a Claim on Credibility, WASH. POST, Dec. 4, 2001, at HE01.
3Pub. L. No. 103-417, 108 Stat. 4325 (codiﬁed at 21 U.S.C. 321, et. seq. (Supp. 1999)).
4E. Randy Eichner, Douglas King, Mark Myhal, Bill Prentice & Tim N. Ziegenfuss, Roundtable: “Muscle Builder” Supple-
ments, Gatorade Sports Science Institute, volume 10, number 3 (1999).
3to assert more regulatory control over dietary supplements5have been frustrated by the supplement indus-
try’s well-ﬁnanced lobbying campaign, with substantial help from many inﬂuential members of Congress,
primarily senators Orrin Hatch, Republican of Utah, and Tom Harkin, Democrat of Iowa.6DSHEA has made
meaningful regulation of dietary supplements by the FDA nearly impossible, especially given FDA’s budget
constraints and the economic and political inﬂuence of the dietary supplement industry. In essence, DSHEA
entrusts the regulation of dietary supplements to the supplement manufacturers themselves, creating a sit-
uation in which consumer safety may be jeopardized in the name of corporate proﬁt.
Perhaps the most striking example of the FDA’s inability to insure the safety of dietary supplements under
DSHEA is in its continuing, and thus far unsuccessful, battle to place more restrictive regulations on sup-
plements containing ephedra alkaloids. Despite mounting anecdotal evidence of ephedra-related injury and
death, and recent studies published in the New England Journal of Medicine (NEJM) and the Mayo Clinic
Proceedings concluding that that ephedra alkaloids may pose a serious health risk to some people,7dietary
supplements containing ephedra are sold without restriction everywhere from gas stations to health food
stores.8This paper examines the possible dangers posed by dietary supplements containing ephedra, the
FDA’s struggle to regulate these supplements under DSHEA and changes in existing law that may help the
FDA more eﬀectively protect the safety of dietary supplement users. Section II provides a brief overview
of ephedra and its various uses as a dietary supplement. Section III examines the documented dangers
associated with ephedra use. Section IV explains how ephedra, and other dietary supplements, are reg-
5Dietary Supplements Containing Ephedra Alkaloids, 62 Fed. Reg. 30678 (proposed June 4, 1997).
6Paul Solotaroﬀ, Killer Bods, ROLLING STONE, Feb. 14, 2002, at 54.
7Christine A. Haller & Neal L. Benowitz, Adverse Cardiovascular and Central Nervous System Events Associated With Di-
etary Supplements Containing Ephedra Alkaloids, 343 N ENGL J MED. 1833, 1837 (2000); David Samenuk, Mark Link, Munther
Homoud, et al., Adverse Cardiovascular Events Temporally Associated With Ma Huang, an Herbal Source of Ephedrine, 77
MAYO CLIN. PROC 12, 12-16 (Jan. 2002).
8Paul Solotaroﬀ, supra note 6, at 59.
4ulated under DSHEA, and details eﬀorts by the FDA and local governments to place tighter regulatory
controls on supplements containing ephedra alkaloids. Finally, Section V oﬀers recommendations for more
eﬀective regulation of ephedra and other potentially dangerous dietary supplements. The paper concludes
that the FDA is unable, under current law and budgetary restrictions, to adequately insure the safety of
dietary supplement consumers, as illustrated by the FDA’s battle against ephedra alkaloids. The author
recommends the following changes to the existing law: 1) require pre-market testing of dietary supplements;
2) require mandatory reporting of adverse events possibly related to dietary supplements; and 3) require
accurate content labels on dietary supplements.
II.
EPHEDRA AS A DIETARY SUPPLEMENT
Ephedra alkaloids are derived from the Chinese herb ephedra, a 5000-year-old Chinese remedy for asthma
and ﬂu, and are found in many popular herbal dietary supplements in the United States.9Ephedrine is the
beneﬁcial chemical component of the ephedra herb and has been used in over-the-counter ﬂu and asthma
medications in the United States for years.10It is chemically similar to the addictive illegal drug metham-
phetamine, diﬀering by only one atom, and similarly acts to stimulate the nervous and cardiovascular sys-
tems.11Ephedrine is simply an isolated form of the chemical compound found in the ephedra herb. Once
they enter the bloodstream, ephedrine and herbal ephedra are the same substance having the same physio-
9Keith Epstein, Findings of Fact: A Reality Check on Product Claims, WASH. POST, May 2, 2000, at Z08.
10Id. Examples of over-the-counter ﬂu and asthma medications currently sold in the United States include Sudafed and
Sinutab, which both contain pseudoephedrine (synthetic ephedrine).
11Id.
5logical eﬀects.12 Ephedra alkaloids are found in an increasing number of dietary supplements, are sold under
many diﬀerent ingredient names13and are contained in variety of colorfully named and marketed products in
powder, pill, bar, chewing gum, and drink form.14Products containing ephedra alkaloids can be found nearly
everywhere, from convenience store check-out lines to herbal health food stores.
The primary uses of ephedra as a dietary supplement are to facilitate weight loss and increase energy. Such
goals are shared by a wide variety of supplement users, including elite athletes who desire a boost of energy
before training or competition, people attempting to treat obesity, and the average person looking for extra
energy to get them through the day.15The fact that the beneﬁcial eﬀects of ephedra alkaloids are commonly
desirable to many diﬀerent types of supplement users, combined with its ease of availability and aggressive
marketing by manufacturers, has made it overwhelmingly popular in the dietary supplement market. Sales
of supplements containing ephedra alkaloids rose to $1 billion in 2000, up from $800 million in 1999.16Three
billion doses of ephedra supplements were sold in 1999 with an estimated 12 million American consumers.17
12Guy Gugliotta, Woman Wins $13.3 Million Against Dietary Company, WASH. POST, Feb. 8, 2001, at A08. The fact that
ephedrine and ephedra have the same physiological eﬀects they are in the human bloodstream is to be expected since ephedra
is merely an herbal source of ephedrine.
13Paula Kurtzweil, An FDA Guide to Dietary Supplements, FDA CONSUMER, Sep. – Oct. 1998 (revised Jan. 1999).
Ingredient names for ephedra alkaloids include ephedra, ephedrine, ma huang, Chines ephedra, epitonin, sida cordifolia, methyl
ephedrine, Chinese joint-ﬁr, bitter orange, country mallow and Brigham’s tea. Benedict Carey, Risks of Ephedra Usage in
Spotlight, L.A. TIMES, Aug. 27, 2001, at Health Section.
14Names of dietary supplements that contain ephedra alkaloids include Metabolife 356, Ripped Fuel, Diet Fuel, Stacker 3,
Natural TRIM, Hydroxycut, Xenadrine RFA-1, Metab-O-Lite, Metabolift, Up Your Gas, Truckers Luv It, Yellow Jackets, Red
Rage, Ultimate Orange and Shape Fast. Benedict Carey, supra note 13.
15Interview with Matthew Howard, northern California construction worker, in Berkeley, Cal. (Mar. 2, 2002) (noting that
many co-workers on job sites consume ephedra supplements, often at multiples of the recommended maximum dosage, to wake
up in the morning and get them through the day).
16Sally Squires, supra note 2.
17Benj Vardigan, Ephedra: One Year Later, Nov. 7, 2001, available at
http://www.buildingbetterhealth.com/topic/ephnﬂ? requestid=80527.
6In addition to its use as a nutritional supplement, ephedra also has been marketed and used as an alternative
to the illegal street drug ecstasy.18Many ephedra alkaloid products have been promoted and advertised on the
internet and in magazines “under a variety of brand names with claims implying that these products mimic
the eﬀects of controlled substances,” but are herbal or all-natural.19Ephedra-based street drug alternatives
came under scrutiny following the March 1996 death of Peter Schlendorf, a 20-year-old State University of
New York at Albany student, who consumed twice the recommended dosage of an ephedrine product called
Ultimate Xphoria while on spring break in Panama City Beach, Florida.20Mr. Schlendorf’s death heightened
public concern regarding “herbal ecstasy” and alerted the popular media to ephedrine use, particularly by
college students, as a substitute for illicit street drugs. In April 1996, the FDA issued a warning, stating that
“consumers should not buy or consume ephedrine-containing dietary supplements whose labels portray them
as apparent alternatives to illegal street drugs,”21and both Nassau County, New York and the state of Florida
placed restrictions on the sale of ephedrine products.22The FDA announced a stronger stance in opposition to
the marketing of ephedrine products as alternatives to illicit drugs in a March 2000 Talk Paper and Guidance
for Industry, introducing a new policy that states, in part, “street drug alternatives are unapproved and
misbranded drugs that can be subject to regulatory action, including seizure and injunction.”23The FDA
was able to place greater restrictions on ephedrine products promoted as “legal drugs” only because it decided
18Peter A. Vignuolo, The Herbal Street Drug Crisis: An Examination of the Dietary Supplement Health and Education Act
of 1994, 21 SETON HALL LEGIS. J. 200, 200-02 (1997).
19U.S. Food and Drug Administration, Guidance for Industry: Street Drug Alternatives (Mar. 2000), available at
http://www.fda.gov/OHRMS/DOCKETS/98fr/001119gl.pdf
20Peter A. Vignuolo, supra note 18, at 200; June Weintraub, Adverse Eﬀects of Botanical and Non-Botanical Ephedrine
Products (1997), available at http://www.hsph.harvard.edu/Organizations/DDIL/ephedrine.html.
21FDA Talk Paper, FDA Announces the Availability of New Ephedrine and “Street Drug Alternative” Documents (Mar. 31,
2000), available at http://www.cfsan.fda.gov/∼lrd/tpephedr.html.
22Peter A. Vignuolo, supra note 18, at 228.
23U.S. Food and Drug Administration, supra note 19 (stating that “FDA considers any product that is promoted as a street
drug alternative to be an unapproved new drug and a misbranded drug in violation of sections 505 and 502 of the Federal Food,
Drug, and Cosmetic Act. Such violations may result in regulatory action, including seizure and injunction”).
7that such products are intended for recreational use to aﬀect psychological states, and therefore do not fall
under the deﬁnition of dietary supplement as deﬁned in the DSHEA.24
III.
THE DANGERS OF EPHEDRA
A.
Increased Risk of Injury or Death
Like its chemical relative methamphetamine, ephedra stimulates the nervous and cardiovascular systems,
increasing the risk of adverse physical events in the human body including hypertension (high blood pres-
sure), stroke, heart attack and seizure.25An analysis of the FDA Adverse Event Report (AER)26database by
consumer group Public Citizen27showed that between January 1993 and February 2000 the FDA received
1,398 reports of adverse events associated with ephedra and ephedra-related products, 81 of which were
2421 U.S.C. 321(ﬀ) (deﬁning the term “dietary supplement”).
25Christine A. Haller & Neal L. Benowitz, supra note 7, at 1836; David Samenuk, Mark Link, Munther Homoud, et al.,
supra note 7, at 15 (ﬁnding that (1) ma huang use is temporally related to stroke, myocardial infarction, and sudden death;
(2) underlying heart or vascular disease is not a prerequisite for ma huang-related adverse events; and (3) the cardiovascular
toxic eﬀects associated with ma huang were not limited to massive doses); Public Citizen, Public Citizen Calls on FDA to Ban
Dietary Supplements Containing Ephedra (Sept. 5, 2001), available at http://www.citizen.org/pressroom/release.cfm?ID=654.
Other reported symptoms of ephedra use include nervousness, dizziness, tremors, changes in heart rate, headache,
stomach trouble and psychosis. Linda Ciampa, Public Hearings Probe Ephedra Safety (Aug. 9, 2000), available at
http://www.cnn.com/2000/HEALTH/alternative/08/09/ephedra.controversy/index.html.
26In 1993 the FDA established its Special Nutritional Event Monitoring System to receive voluntary reports of illnesses and
death from dietary supplements. Guy Gugliotta, FDA Takes Aim at Ephedra, WASH. POST, Mar. 19, 2000, at A22. The
FDA’s AER database includes “voluntary reports from public health agencies, consumers and health professionals of adverse
events related to nutritional supplements.” Public Citizen, supra note 25.
27Public Citizen is a national, nonproﬁt consumer advocacy organization founded by Ralph Nader in 1971 to represent
consumer interests in Congress. Public Citizen, supra note 25.
8deaths.28The number of adverse events attributable to ephedra is certainly higher than the FDA’s numbers
indicate because reporting of AER’s is voluntary, even for dietary supplement manufacturers.29 Ephedra
manufacturers, distributors and lobbyists, such as the Ephedra Education Council, point to the fact that
no scientiﬁc study has proved a causal link between ephedra and injury or death, when ephedra-containing
supplements are used as directed.30The ephedra industry also criticizes the FDA’s data on AER’s as ﬂawed
and incomplete. Those arguing that ephedra is safe cite two recent studies supporting their position. One
study performed by Cantox Health Science International found that consuming ephedra under certain spec-
iﬁed conditions results in a low occurrence of adverse reactions.31According to the Cantox study, conditions
for the safe use of ephedra include:
1.
Dosage limits of 90 mg per day, with no more than 30 mg per dose.
2.
28Id. “Of the 3,309 adverse events analyzed, 1,398 were associated with ephedra and related substances, or 42 percent.
Of those, there were 81 deaths, 32 heart attacks, 62 reports of cardiac arrhythmia, 91 reports of hypertension, 69 strokes
and 70 seizures. Ephedra is also associated with sleep disturbance, personality disorders, agitation, headaches, hallucinations,
gastrointestinal problems and skin eruptions.” Id.
29Rita Rubin, Consumer Group: FDA Must Ban Ephedra (Sep. 5, 2001), available at
http://www.usatoday.com/news/healthscience/health/2001-09-06-ephedra-usat.htm. Trial lawyer Chris Grell took a de-
position from a dietary supplement company executive who said the company had received “roughly 3,500 complaints” about
its ephedrine product, none of which had been reported to the FDA. Guy Gugliotta, supra note 26. As an example of chronic
underreporting, Public Citizen states that “the Texas Department of Health reported approximately 500 adverse events related
to ephedra between December 1993 and September 1995.” Public Citizen, supra note 25.
30Ephedra Education Council, Scientiﬁc Studies and Reports (2001), available at
http://www.ephedrafacts.com/studies.html#newengland (noting that the authors of the NEJM article concede that
their study does not prove causation nor does it provide quantitative information with regard to risk, and claiming that “[all]
studies and reports have demonstrated that ephedra products are safe and eﬀective in contributing to weight loss when used
as directed.”
31Cantox Health Sciences International, Safety Assessment and Determination of a Tolerable Upper Limit for Ephedra (Dec.
19, 2000) available for download at http://www.crnusa.org/CRNCantoxreportindex.html.
9Labeling to provide exclusions and contraindications consistent with the 19 clinical trials it performed.
a.
Contraindicated for some persons
b.
Check with healthcare provider about use
c.
Limit use to 6 months or less
d.
Not for anyone under 18 years old
3.
Post-market monitoring.32
The Cantox study, however, was funded by an ephedra trade group, the Council for Responsible Nutrition,
and thus its ﬁndings may be viewed with some skepticism.33 A joint study by Harvard Medical School
and Columbia University, conducted by Dr. Carol Boozer, et al., is also cited to support the relative
33Id.; Ephedra Education Council, Scientiﬁc Studies and Reports (2001), available at
http://www.ephedrafacts.com/studies.html#cantox.
10safety of ephedra.34It found that subjects given an ephedra/caﬀeine combination experienced lowered weight
and body fat, and had symptoms similar to subjects given an ephedrine/caﬀeine combination, including
increased heart rate and blood pressure.35These results are merely consistent with the fact that ephedra is
an herbal source of ephedrine, and aﬀects the human body in the same manner. Like the Cantox study, the
Harvard/Columbia study was funded by an ephedra industry trade group.36
Proponents of tighter ephedra regulation point to an in-depth review of 140 of the FDA’s AER’s performed
by Dr. Christine Haller and Dr. Neal Benowitz of the University of California at San Francisco, and pub-
lished in the New England Journal of Medicine (NEJM).37The study, funded in part by the FDA, concluded
that consuming ephedra alkaloids had no demonstrated beneﬁt and that “dietary supplements that contain
ephedra alkaloids pose a serious health risk to some users.”38As a possible explanation for why other studies
have found little risk in consuming moderate amounts of ephedra, the authors suggest that serious adverse
events may be due to “individual susceptibility, the additive stimulant eﬀects of caﬀeine, the variability in
the contents of pharmacologically active chemicals in the products, or preexisting medical conditions.”39The
authors concede that their study “does not prove causation, nor does it provide quantitative information
with regard to risk,” but they maintain that supplements containing ephedra alkaloids should be consid-
ered “unreasonably dangerous,” especially for people with unrecognized risk factors such as cardiovascular
34Ephedra Education Council, Scientiﬁc Studies and Reports (2001), available for download at
http://www.ephedrafacts.com/studies.html#harvard.
35Id.
36Guy Gugliotta, Report Disputes Ephedra Dosage, WASH. POST, Dec. 21, 2000, at A12.
37Christine A. Haller & Neal L. Benowitz, supra note 7.
38Id. at 1838.
39Id. at 1837.
11disease.40They suggest a large-scale case-control study to determine the risks associated with dietary sup-
plements containing ephedra alkaloids.
Another study, recently published in the Mayo Clinic Proceedings, found substantial temporal association
with reported adverse events and ingestion of ephedra alkaloids.41An editorial published in the same issue of
the Mayo Clinic Proceedings argues that the study, along with the NEJM study, should not be dismissed due
to the lack of an established causal relationship between adverse events and ephedra alkaloids, but instead the
ﬁndings signal a need for more substantive investigations.42The editorial states that, “[r]andomized placebo-
controlled studies are needed to establish the magnitude of risks associated with ephedrine alkaloids and to
show deﬁnitively whether these dietary supplements constitute a public health menace.”43Completion of a
comprehensive large-scale study, like the one suggested in the Mayo Clinic Proceedings, is the only way to
provide reliable scientiﬁc evidence of the safety of ephedra alkaloids as dietary supplements.
Aside from the dangers of an immediate adverse reaction to an ephedra product, at least one study has
suggested that users may become addicted to ephedra alkaloids.44Dr. Amanda Gruber, associate chief of
substance abuse in the biological psychiatry laboratory of the Harvard-aﬃliated McLean Hospital, conducted
a 1998 study of 36 female athletes, and found that nearly 20 percent of them showed “frank ephedrine
40Christine A. Haller & Neal L. Benowitz, To the Editor, 344 N ENGL J MED. 1096, 1096-97 (2001) (in response to a
letter to the editor of the New England Journal of Medicine that suggested that ephedra was likely neither the cause of, nor a
contributing factor to, the adverse events studied by Haller and Benowitz).
41David Samenuk, Mark Link, Munther Homoud, et al., supra note 7, at 15.
42Bruce D. Lindsay, Are Serious Adverse Cardiovascular Events an Unintended Consequence of the Dietary Supplement
Health and Education Act of 1994?, 77 MAYO CLIN. PROC. 7, 7-9, (January 2002).
43Id. at 8.
44Benj Vardigan, Bad Business, Part I: Ephedra Supplements, Jul. 12, 2000, available at
http://www.buildingbetterhealth.com/topic/ephreport1? requestid=76632 (last updated Aug. 1, 2001).
12dependence.”45Her ﬁnding was based on the subjects “needing increased dosages to achieve the desired eﬀects,
experiencing withdrawal symptoms after discontinuing its use, and attempting many times – unsuccessfully
– to stop taking ephedra.”46A link between ephedra and addiction has not been proved, but questions
surrounding such a link may be resolved by conducting a scientiﬁc study such as the one previously proposed.
B.
Combining Ephedra with Other Stimulants
Many dietary supplements containing ephedra also contain one or more additional stimulants, usually caf-
feine.47Caﬀeine is often listed in its herbal form such as guarana or kola nut on the label of dietary sup-
plements, and thus supplement users may not know that they are ingesting multiple stimulants.48As noted
in the NEJM study, caﬀeine is likely to enhance the stimulant eﬀects of ephedra and may put the user at
greater risk of an adverse event.49The NEJM cites a study on interaction between phenylpropanolamine,
also an ephedra alkaloid, and caﬀeine that found that the two drugs have an additive eﬀect on blood pres-
sure.50Combining phenylpropanolamine and caﬀeine in one product was banned by the FDA in 1983 due
to health risks.51Users of dietary supplements that combine ephedra alkaloids and caﬀeine may also ingest
45Id. at 4.
46Id.
47Paul Solotaroﬀ, supra note 6, at 58. Referred to as “stacks,” combining multiple active ingredients into a single dietary
supplement has become popular in the supplement industry. Id.
48Benj Vardigan, supra note 44, at 1.
49Christine A. Haller & Neal L. Benowitz, supra note 7, at 1837. “By inhibiting adenosine-mediated dilatation of blood vessels,
caﬀeine constricts blood vessels and may increase blood pressure in persons prone to hypertension. Caﬀeine also augments the
release of catecholamines, an eﬀect that, when combined with that of ephedrine, could lead to increased stimulation of the
central nervous system and cardiovascular system.” Id.
50Id.
51Id.
13high quantities of caﬀeine in their daily lives, unknowingly putting themselves at greater risk of an adverse
reaction caused by drug interaction. Yet many dietary supplement users remain unaware of the dangers
associated with the additive eﬀects of such substances.
Even savvy supplement users who carefully keep track of the amounts of ephedra alkaloids and caﬀeine
they ingest may unintentionally consume a dangerous amount of stimulants if the product labels of the
supplements they are taking incorrectly list ingredient amounts. The NEJM article cites a study by Gurley
et al. that found that 11 of 20 ephedra supplements tested “either failed to list the alkaloid content on
the label or had more than a 20 percent diﬀerence between the amount listed on the label and the actual
amount.”52Correctly labeling the amount of ephedra alkaloids in dietary supplements is of great importance
to the public health and should be strictly regulated and enforced by the FDA.
C.
Misleading Marketing and Advertising
Ephedra-containing dietary supplements are marketed in a variety of ways, depending upon the character-
istics of the target consumer. Ephedra supplements found in natural food stores or targeted to an older
consumer base are often marketed as a safe, herbal, all-natural way to lose weight or increase energy lev-
els, and have names such as Natural TRIM, Metabolife or Metab-O-Lite.53Ephedra supplements aimed at
attracting high school kids and young adults are sold in places like gyms or convenience stores and go by
names such as Ripped Fuel, Red Rage or Thermo Speed, to indicate their potency and quick results.54Product
52Christine A. Haller & Neal L. Benowitz, supra note 7, at 1837.
53Public Citizen, supra note 25, at 1; Guy Gugliotta, Health Concerns Grow Over Herbal Aids, WASH. POST, Mar. 19,
2000, at A01.
54Paul Solotaroﬀ, supra note 6, at 58.
14packaging is also key in attracting consumers, with supplements commonly sold to young adults packaged in
brightly colored bottles or wrapping, with outrageous claims printed on them. Ephedra manufacturers have
designed products intended to appeal to nearly every demographic in America. Whether your goal is weight
loss, enhanced athletic performance or increased energy, the ephedra industry will try to convince you that
ephedra will help accomplish it.
The fact that dietary supplements containing ephedra are legal and readily available contributes to the
popularly held perception that the supplements are safe.55Consumers are also lulled into a false sense of
security by supplements marketed as “herbal” or “natural,” believing these labels connote safety. There also
exists the misconception that the government, or FDA, would not allow a harmful product to remain on
the market, especially a widely available product that purports to promote good health.56Misplaced reliance
on governmental paternalism and the mistaken belief that “all-natural” products are safe likely contribute
to the popularity of dietary supplements containing ephedra. If the FDA cannot succeed in placing tighter
restrictions on potentially dangerous products, as in the case of supplements containing ephedra alkaloids, it
should at least alert the public to the actual dangers of such products so that consumers can make informed
choices without relying on incomplete and erroneous information or a false sense of security.
Ephedra manufacturers have gone to great lengths to promote the safe and natural image of their products
and have diligently resisted eﬀorts by the FDA, or others, to warn the public of possible dangers related
55Id. at 56.
56“Look, all that stuﬀ’s legal. If it was dangerous, they couldn’t put it out there,” stated Alex Zarnas, a high school student
and supplement user. Id. “The increased occurrence of adverse events related to ephedrine consumption may be partly blamed
on misleading marketing, poor labeling and the pervasive misconception of safety.” June Weintraub, supra note 20.
15to ephedra use. Some manufacturers have avoided reporting adverse reactions from the use of their prod-
ucts, fought FDA attempts at imposing more stringent regulations on ephedra and brought lawsuits against
individuals for publicly claiming that ephedra is potentially dangerous.57A deposition taken in 1999 from
a company executive of E’ola International, a manufacturer of dietary supplements containing ephedrine,
revealed that the company had received “roughly 3,500 complaints” about its ephedrine product, none of
which were reported to the FDA.58Metabolife International, one of the biggest dietary supplement manu-
facturers in the nation, recently brought a law suit against a television station, a reporter, and a physician
based on a show depicting the possible dangers of Metabolife pills.59The founder of Metabolife and president
of a supplements industry coalition, Michael Ellis, who was arrested in 1990 for conspiring to manufacture
methamphetamine, has been one of the leaders of a successful lobbying campaign that has, thus far, blocked
federal regulators who wish to place greater restrictions on ephedra because of safety concerns.60The use
of creative marketing combined with a powerful lobbying eﬀort have helped the ephedra industry downplay
the possible dangers of their products, and have contributed to the billion-dollar industry’s rapid growth in
recent years.
57Rita Rubin, supra note 29; Benj Vardigan, supra note 44. Some members of the medical profession believe that physicians
may be hesitant to publish or publicize adverse events because they fear being sued by ephedra manufacturers. Bruce D.
Lindsay, supra note 42, at 8.
58Guy Gugliotta, supra note 53, at A01.
59Metabolife Int’l v. Wornick, 264 F.3d 832 (9th Cir. 2001).
60Id.; Sean Elder, The Skinny on Damage Control (Oct. 20, 1999), available at
http://www.salon.com/media/feature/1999/10/20/media/ (noting that Mr. Ellis eventually pled guilty to a lesser charge).
16D.
Children Taking Ephedra
Many ephedra supplements carry labels stating that the product is not intended for use by anyone under 18
years old, but there is no federal law preventing the sale of ephedra to children. Evidence shows that chil-
dren are increasingly becoming users of ephedra.61Although ephedra manufacturers deny that they market
to children, kids often are attracted to ephedra products in fruit punch or gum form with brightly colored
packaging and claims that appeal to younger consumers.62Ephedra presents an even greater danger to chil-
dren than to adults because kids are less likely to use appropriate caution when taking dietary supplements
and may intentionally take more than the recommended dosage because they are unaware of any possible
negative eﬀects or because they miscalculate the danger of the product.63Children today also are aware of
the “legal high” eﬀects of ephedra, and may be more likely than adults to overdose on ephedra while using
it as a substitute for illicit drugs.
IV.
FDA REGULATION OF EPHEDRA UNDER DSHEA
A.
61Guy Gugliotta, Diet Supplement Marketers Target Kids, WASH. POST, June 18, 2000, at A01. Of the 140 adverse events
analyzed in the NEJM study, at least 10 were under age 18. Christine A. Haller & Neal L. Benowitz, supra note 7, at 1834;
Paul Solotaroﬀ, supra note 6, at 74 (stating that at the General Nutrition Store visited by the author, children as young as 14
years old were allowed to buy ephedra supplements).
62Paul Solotaroﬀ, supra note 6, at 58 (noting label claims such as, “[w]ill hit you like a goddamn knockout punch!”).
63Id. at 72. “Seemingly every day, I get a call from another kid who’s been hurt by ephedrine,” said John Tiedt, personal
injury lawyer from Los Angeles. Id.
17How DSHEA Has Aﬀected Regulation of Dietary Supplements
The Dietary Supplement Health and Education Act of 1994 amended the Food, Drug and Cosmetic Act,
creating a new category of products deﬁned as dietary supplements, a subset of foods, and changed the
regulatory authority of the FDA over dietary supplements. Under DSHEA, the deﬁnition of “dietary sup-
plement” includes:
•
A product (other than tobacco) that is intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total daily intake, or a concentrate, metabolite, constituent, extract, or combinations of these ingredients.64
•
A product intended for ingestion in pill, capsule, tablet, or liquid form.65
•
A product not represented for use as a conventional food or as the sole item of a meal or diet.66
•
A product labeled as a “dietary supplement.”67
•
Products such as an approved new drug, certiﬁed antibiotic, or licensed biologic that was marketed as a dietary supplement or food before approval, certiﬁcation, or license (unless the Secretary of Health and Human Services waives this provision).68
Two signiﬁcant changes brought about by the passage of DSHEA have resulted in the FDA’s diminished
ability to protect consumers of dietary supplements from harm. First, products falling under the deﬁnition
of “dietary supplement” are not required to undergo a pre-market approval process.69It is now the sole
69Laura W. Khatcheressian, supra note 58, at 627.
18responsibility of the manufacturer to insure that supplements are safe before placing them on the market.
Prior to DSHEA, what are now deﬁned as dietary supplements were regulated by the FDA as either “food
additives” or “drugs,” and under either classiﬁcation the manufacturer was required to prove that the sup-
plement was safe prior to marketing.70DSHEA, however, amended the deﬁnition of food additive to explicitly
exclude dietary supplements.71Dietary supplements avoid regulation as drugs as long as manufacturers do
not claim the product prevents, treats, or cures a disease.72Consequently, DSHEA has completely eliminated
the FDA’s role in determining whether dietary supplements are safe when they come to market.
Second, DSHEA has dramatically weakened the FDA’s ability to remove a potentially dangerous dietary
supplement from the market. In order to remove a supplement from the market the FDA bears the burden
of proving that the product is “adulterated.”73Under DSHEA, a dietary supplement is adulterated if it
presents “a signiﬁcant or unreasonable risk of illness or injury” when used as directed on the label.74By
placing the burden of proving dietary supplements “adulterated” on the FDA and requiring no pre-market
assurance of safety, DSHEA has eﬀectively entrusted the health and safety of dietary supplement consumers
to supplement manufacturers.
70Id. at 626; Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining
Government Regulation Five Years After Enactment of the Dietary Supplement Health and Education Act of 1994, 54 FOOD
DRUG L.J. 567, 567-586 (1999). FDA can prohibit the marketing of a new dietary ingredient “for which there is inadequate
information to provide reasonable assurance that such ingredient does not present a signiﬁcant or unreasonable risk of illness or
injury.” 21 U.S.C. 342(f)(C) (1999). Among other restrictions, “new dietary ingredient” does not apply to ingredients marketed
in the United States prior to the passage of DSHEA in October 1994. 21 U.S.C. 350(b)(c) (1999).
7121 U.S.C. 321(s)(6) (1999); Jennifer J. Spokes, Confusion in Dietary Supplement Regulation: The Sports Product Irony,
77 B.U.L. Rev. 181, 191-92 (1997).
72Guy Gugliotta, FDA Rule Provides Wide Leeway for Diet Claims, WASH. POST, Jan. 6, 2000, at A2.
7321 U.S.C. 342(f)(1) (1999).
7421 U.S.C. 342(f)(1)(A) (1999).
19B.
FDA’s Proposed Safety Measures
Although stripped of most of its regulatory power over dietary supplements, the FDA has continued to
ﬁght, albeit unsuccessfully, for tighter regulation of ephedra. The FDA created a special working group
in 1995 to evaluate the potential public health problems associated with dietary supplements containing
ephedra. In June 1997, in response to the working group’s recommendations and the growing number of
AER’s originating from ephedra use, the FDA released proposed safety measures for ephedra-containing
dietary supplements.75The FDA proposed to:
1.
limit the dose of ephedrine alkaloids to eight milligrams (mg) per six-hour period or a total of 24 mg per day;
2.
require labels to state that the product should not be used for more than seven days;
3.
prohibit use of ephedrine alkaloids in dietary supplements with ingredients such as caﬀeine, which have known stimulant eﬀects;
4.
prohibit inaccurate labeling claims; and
75U.S. Food and Drug Administration, supra note 5.
205.
require a warning label statement on some ephedrine alkaloid products that state, “Taking more than the recommended serving may result in heart attack, stroke, seizure or death.”76
If the proposal were adopted it would severely limit the uses of ephedra alkaloids in dietary supplements,77and
accordingly, it generated an overwhelmingly negative response from the ephedra industry and the industry’s
supporters in Congress.78The General Accounting Oﬃce (GAO), Congress’s investigative branch, reviewed
the proposal and issued a report critical of the FDA’s scientiﬁc basis for the proposal, speciﬁcally GAO
questioned the FDA’s methods of collecting AER’s and the reliance on data from AER’s as a basis for the
proposal.79Based on the GAO’s criticism and the backlash from the ephedra industry, in April 2000 the FDA
withdrew its proposal, in part.80
The failed attempt by the FDA to impose tighter restrictions on the use of ephedra demonstrates its inability
77Prohibiting the use of ephedrine or ephedra products for more than seven days “would essentially ban ephedrine weight-
loss or bodybuilding supplements, because getting those purported health eﬀects requires weeks of use.” Lauran Neergaard,
Ephedrine Crackdown (June 2, 1997), available at http:www.hcrc.org/news/ephedrin/html.
78The strongest supporters of the supplement industry in Congress have been Senator Orrin Hatch (R-Utah) and Senator
Tom Harkin (D-Iowa). Hatch received more than $100,000 from the supplement industry in the last election cycle alone and
Harkin has received at least $72,000 since 1994. Paul Solotaroﬀ, supra note 6, at 56; Guy Gugliotta, Dietary Supplement
Makers Flex Muscle, WASH. POST, Dec. 25, 2000, at A01.
79Bruce D. Lindsay, supra note 42, at 8; U.S. General Accounting Oﬃce, Dietary Supplements: Un-
certainties in Analyses Underlying FDA’s Proposed Rule on Ephedrine Alkaloids (July 2, 1999), available at
http://www.gao.gov/archive/1999/h299090.pdf. Objections included: the FDA failed to establish a causal link between ephedra
and the adverse events; some consumers deliberately overdosed themselves; and that some consumers ignored warnings about
drug interactions and pre-existing medical conditions. Guy Gugliotta, supra note 26, at A22.
80FDA withdrew its proposals to limit 1) the ephedrine alkaloid level and 2) duration of use. Dietary Supplements Containing
Ephedrine Alkaloids; Withdrawal in Part, 65 Fed. Reg. 17474 (April 3, 2000). Congress claimed that the AER’s “were sloppy,
incomplete and poorly documented.” Guy Gugliotta, supra note 26, at A22.
In April 2000, FDA continued to push for a restriction against the combination of ephedra and other stimulants, and stricter
warning labels to highlight the potential for serious injury or death. It collected 134 new AER’s between June 1, 1997 and
March 31, 1999. The ephedra industry once again criticized the lack of an established causal connection between the adverse
events and ephedra and cited the fact that some adverse events may have resulted from consumers deliberately overdosing or
ignoring warnings about drug interaction and pre-existing medical conditions. It has yet to be seen whether FDA will pursue
its ﬁght for tighter regulations on ephedra in the near future. Id.; Ori Twersky, Ephedra Safety Under Oﬃcial Scrutiny, Again
(Aug. 9, 2000), available at http://webmd.lycos.com/content/article/1728.60268.
21to protect the public from potentially dangerous dietary supplements under DSHEA. Adverse Event Reports
are helpful in alerting the FDA to a public health concern, but it is clear that more compelling evidence,
such as a long-term scientiﬁc study, is needed to enable the FDA to place tighter restrictions on the sale
of a dietary supplement, much less remove a dietary supplement from the market.81However, since pre-
market safety testing of dietary supplements is not required by DSHEA, the FDA is severely limited in
its ability to acquire the scientiﬁc evidence that Congress and the ephedra industry claim is needed to
fulﬁll the FDA’s burden of proving a supplement unsafe.82Without additional funding, which Congress has
refused to grant the FDA, the FDA has been forced to rely on AER’s as justiﬁcation for its proposed
restrictions.83Suﬃcient funding to perform, or sponsor, scientiﬁc testing of dietary supplements, along with
mandatory reporting of adverse events associated with supplements are needed for the FDA to eﬀectively
regulate dietary supplements under DSHEA.
C.
Other Attempts At Ephedra Regulation
The FDA’s inability to eﬀectively regulate the safety of dietary supplements under DSHEA has prompted
81Bruce D. Lindsay, supra note 42, at 8.
82Id. “In essence, industry has positioned itself so that well-designed scientiﬁc trials are not required to market dietary
supplements containing ephedrine. However, when allegations are made about the safety of the products, those who have a
vested interest in marketing the supplements decry the lack of scientiﬁc evidence. This argument is reminiscent of tactics used
by the tobacco industry years ago.” Id.
83Paul Solotaroﬀ, supra note 6, at 56. “In eﬀect, Congress handed us a huge new job but no new money to do it. We have
very few ﬁeld staﬀ and no budget at all to compile the kind of proof that would stand up in court. What we need is help from
the public-health community, scientiﬁc evidence that these products are harmful,” stated Dr. Christine Lewis Taylor, director
of the FDA’s Oﬃce of Nutritional Products Labeling and Dietary Supplements. Id.
Senator Tom Harkin, D-Iowa, an ardent supporter of the dietary supplement industry, stated that the FDA “has only itself
to blame” because it has not made a suﬃcient case against ephedra. However, Joseph Levitt, director for the FDA’s Center
for Food Safety and Applied Nutrition, blamed the shortcomings of the June 1997 proposal on a lack of money from Congress.
Levitt noted that Congress has twice refused a $2.5 million request to improve the FDA’s tracking procedures for adverse
reactions to supplements. Guy Gugliotta, supra note 78; Guy Gugliotta, Unlikely Allies, Harkin and Hatch Aid Industry,
WASH. POST, Dec. 25, 2000, at A4.
22some states and local governments to act to impose tighter restrictions on ephedra supplements. As men-
tioned in Section II, Florida and New York banned the sale of some ephedra supplements following the
overdose and death of Peter Schlendorf during spring break.84A number of other states, including California,
Texas, New Jersey, Ohio, and Nebraska have at least attempted to place tighter controls on ephedra supple-
ments.85Congress and the ephedra industry have opposed such attempts by states to more closely regulate
ephedra supplements, arguing that additional state restrictions would result in inconsistent regulation.86
Many athletic organizations, including the International Olympic Committee (IOC), the National Collegiate
Athletic Association (NCAA), and the National Football League (NFL) have banned the use of products
containing ephedra alkaloids. In September 2001, the NFL notiﬁed its clubs that ephedra was placed on its
list of banned substances.87The ban came after the deaths of eleven football players, on both the amateur and
84Peter A. Vignuolo, supra note 18, at 229.
85In California, Governor Grey Davis vetoed a bill in September 2000 that would have required stricter warnings
on labels of supplements containing ephedra and a toll-free number on the product label. The veto came seven
months after the governor received two $50,000 campaign contributions from ephedra industry giant Metabolife. Guy
Gugliotta, supra note 78; Citizens For Health, California Ephedra Bill Vetoed by Governor (Oct. 2, 2000), avail-
able at http://www.citizens.org/DietarySupplements/PressRelease/CalVeto.html. A more recent California bill propos-
ing similar restrictions on ephedra, and an age requirement of 18 years old for its purchase, was introduced to
the state’s Senate Committee on Health and Human Services on March 7, 2002. Senate Bill 1750, available at
http://info.sen.ca.gov/pub/bill/sen/sb 1...50/sb 1750 bill 20020221 introduced.html.
86CBS.com, Food Fight Over States’ Rights (July 15, 2000) available at
http://www.cbsnews.com/stories/2000/07/15/national/printable215616.shtml.
The recent passage of The National Uniformity for Food Act of 2001 raises new questions about states’ ability to regulate
label requirements and dosage amounts more strictly than federal standards. The Act provides for national, uniform labeling
and warning requirements, but would apparently not aﬀect states’ ability to impose age requirements for the purchase of
ephedra products or restrictions on marketing techniques. The website of the Act’s sponsor, Congressman Richard Burr, R-
North Carolina, claims that the bill “does not address dietary supplements.” H.R. 2649, 107th Cong. (2001) available at
http://www.house.gov/burr/RBsBills/food107.htm.
87National Football League press release, NFL Bans Ephedrine, Other Stimulants (Sept. 27, 2001), available at
http://www.nﬂ.com/news/2001/ephedrine 092701.html. The NFL ban also prohibits players from entering into any endorse-
ment arrangements with ephedra supplement manufacturers or distributors. Before the ban, “ephedrine supplements were
endorsed by 2000 NFL MVP Marshall Faulk, Indianapolis Colts running back Edgerrin James and New York Giants receiver
Joe Jurevicius.” Paul Solotaroﬀ, supra note 6, at 58.
23professional level, in 2001 during or immediately following football games or practices.88Although no clear
link to ephedra has yet been established, at least some of those athletes had consumed dietary supplements
containing ephedra shortly before their death, raising concerns about safety.89
Perhaps Congress believed that the threat of tort liability would provide a suﬃcient incentive for ephedra
manufacturers to responsibly police their industry and keep dangerous supplements oﬀ of the market. Al-
though the threat of lawsuits helped prompt manufacturers to place more extensive warnings on product
labels, the deterrent eﬀect of tort liability has so far been insuﬃcient to force the ephedra industry to take
substantive precautionary steps that would endanger their proﬁts, such as the steps proposed by the FDA in
June 1997. The proﬁtability of ephedra products coupled with the diﬃculty in proving that such products
are the cause of any particular injury or death actually provides incentives for ephedra manufacturers to
keep their products on the market. When they are sued, ephedra manufacturers are usually able to avoid
litigation and settle cases out of court. Between 1994 and mid-1999, supplement companies settled at least
33 personal injury and wrongful death lawsuits involving ephedra or ephedrine.90The cases usually settle
quietly with a conﬁdentiality agreement insuring that settlement amounts and any harmful evidence are
kept oﬀ of the public record.91In February 2001, the ﬁrst case involving an ephedrine-related injury to go
88The rash of sudden deaths prompted Henry Waxman, D-California, to urge the FDA to examine the possible role of
ephedra in the deaths. Letter from Henry Waxman, Democratic Congressman, California, to Bernard A. Schwetz, Acting
Principal Deputy Commissioner, Food and Drug Administration (Sep. 10, 2001) (on ﬁle with the author).
Explaining why it imposed the ban on ephedra products, the NFL stated, “These substances [ephedra alkaloid products] present
signiﬁcant health issues for athletes and other engaged in strenuous physical activity.” National Football League press release,
supra note 87.
89Paul Solotaroﬀ, supra note 6, at 59. “Devaughn Darling of Florida State and Rashidi Wheeler of Northwestern both
...collapsed on the practice ﬁeld after taking ephedrine-laced products.” Id.
90Guy Gugliotta, supra note 12.
91“There is no public litigation. Lawsuits either get snuﬀed out real quick, because the [plaintiﬀ] ﬁrms don’t have the [ﬁnancial]
legs to stay the course, or they get settled like tobacco litigation – with a conﬁdentiality agreement,” said Los Angeles trial
lawyer Ward Benshoof who settled a case against Herbalife International in 1997. Guy Gugliotta, Ephedra Lawsuits Show Big
24to trial resulted in a jury award of $13.3 million to an Alaska woman who suﬀered a stroke after taking a
weight-loss supplement containing ephedrine.92The bad publicity of litigation and the cost of settlements has
caused insurers to raise ephedra manufacturers’ liability rates, and has perhaps contributed to much of the
industry voluntarily adopting changes in product labeling aimed at preventing consumers from overdosing.93
Voluntary substantive changes to promote safety, though, have not been a result of the threat of legal liabil-
ity. The tort system’s ability to force eﬀective self-regulation of dietary supplement companies has proved
limited and insuﬃcient. Meaningful federal regulation is needed to protect the public health.
V.
CONCLUSION AND RECOMMENDATIONS FOR MORE EF-
FECTIVE REGULATION OF DIETARY SUPPLEMENTS
Nearly eight years after the passage of DSHEA, a growing body of evidence suggests that the FDA is
unable, under current law and budgetary restrictions, to adequately insure the safety of dietary supplement
consumers. Instead of striking a reasonable balance between consumer access to dietary supplements and
safety, DSHEA compromises the safety of all supplement users. By allowing dietary supplements to enter
the market before they are proved safe and by making it very diﬃcult to remove supplements once they have
reached the market, DSHEA signals a belief by Congress that consumer access to dietary supplements is
Increase, WASH. POST, July 23, 2000, at A01.
92Guy Gugliotta, supra note 12 (ﬁnding E’Ola International liable for creating an unsafe product, misrepresenting it as all
“natural” when it contained synthetic ephedrine in addition to herbal ephedra, and for being negligent in failing to make changes
in the product despite warnings from state and federal authorities that it could cause serious illness, including stroke). Id.
93Id.
25more important than public safety. It is time for Congress to act to correct the dangerous imbalance caused
by DSHEA. The following changes to DSHEA would allow the FDA to more eﬀectively protect consumers
of dietary supplements:
1.
Require pre-market testing of dietary supplements.
Pre-market testing of supplements that have a questionable history of safety, or new supplements which
have no safety record at all, would help insure that supplements on the market are safe. Consumers may
not be as well-informed about the potential dangers of dietary supplements as Congress assumed in passing
DSHEA. Warnings printed on product labels are a step in the right direction but some consumers ignore
such warnings, dismissing them as simply a by-product of our litigious society. Many Americans gauge the
danger of a product based on the product’s range of availability , how it is advertised and where it is sold.
Reliance on governmental paternalism for some degree of protection gives rise to the belief that a dietary
supplement that may cause sudden death or injury, and yet is widely available and advertised to promote
good health, simply would not be allowed on the market. A pre-market testing process, while expensive
and time-consuming, would help prevent dangerous supplements from entering the market without unduly
inhibiting consumer access to advantageous supplements.
Pre-market testing of dietary supplements would also aid post-market regulation of dietary supplements.
Requiring adequate scientiﬁc testing of questionable dietary supplements before they can be sold on the
market would provide much needed scientiﬁc evidence of the safety and possible dangers of supplements.
With a testing system already in place, post-market testing of suspicious supplements would be made much
more eﬃcient and practical. A system of scientiﬁc supplement safety testing would allow the FDA to make
better evaluations of whether to remove a supplement from the market, and help the FDA meet its burden
26of proving a potentially dangerous supplement adulterated, if necessary.
2.
Require dietary supplement manufacturers and distributors to report all known instances of adverse events possibly related to their products to the FDA.
Mandatory reporting of adverse events would provide circumstantial evidence of injuries and illnesses stem-
ming from supplement use. Such evidence would alert the FDA to possible health risks and allow for more
eﬀective tracking of supplement safety. Decisions regarding post-market testing would also beneﬁt from the
information gained by mandatory reporting.
3.
Require accurate content labels on dietary supplements.
Many dietary supplement labels incorrectly list the amounts of active ingredients in their products, putting
even a knowledgeable and careful consumer at risk. The FDA should routinely test dietary supplements
to make sure the stated ingredient amounts on the labels correspond to the amounts actually found in the
products.
27ENDNOTES
28